Begin main content


Last Updated: August 28, 2019
Result type: Reports
Project Number: SR0631-000
Product Line: Common Drug Review

Generic Name: siponimod

Brand Name: Mayzent

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Multiple sclerosis

Manufacturer Requested Reimbursement Criteria1:

​​For the treatment of patient with secondary progressive multiple sclerosis.

Submission Type: New

Project Status: Pending

Call For Patient Input: August 28, 2019

Patient Input Closed: October 18, 2019

Anticipated Date: September 26, 2019

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback